Global Postmenopausal Vaginal Atrophy Treatment
Global Postmenopausal Vaginal Atrophy Treatment

Postmenopausal Vaginal Atrophy Treatment Comprehensive Study by Drug Form (Vaginal gel, Creams, Tablet, Others), Drug (Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring), Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm), Others), Route of Administration (Oral, Intravaginal, Others), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2025

Postmenopausal Vaginal Atrophy Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Sep 2020 Edition 232 Pages 175 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Postmenopausal Vaginal Atrophy Treatment Market Scope
Postmenopausal vaginal atrophy is the thinning of the walls of the vagina caused by decreased estrogen levels. This most commonly occurs after menopause. Women with vaginal atrophy have a greater chance of chronic vaginal infections and urinary function problems. The most common symptoms of vaginal atrophy are dryness, irritation, and pain during intercourse. The postmenopausal vaginal atrophy Treatment market is expected to grow in the future due to rising awareness about the treatment among the women and rising R& D activities for new treatments.

The market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Postmenopausal Vaginal Atrophy Treatment market throughout the predicted period.

Actavis Generics (United States), Bionovo (Saudi Arabia), Endoceutics, Inc. (Canada), Upsher-Smith Laboratories, LLC (United States), Novo Nordisk A/S (Denmark), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Isreal), Therapeutics MD, Inc. (United States), Shionogi & Company, Limited (Japan), Allergan plc (Ireland), Ligand Pharmaceuticals (United States) and Bayer HealthCare LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Pantarhei Bioscience (Netherland) and VYNE Therapeutics Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Postmenopausal Vaginal Atrophy Treatment market by Type, Application and Region.

On the basis of geography, the market of Postmenopausal Vaginal Atrophy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Mar 2020, Menlo Therapeutics Inc announced the completion of its merger with Foamix Pharmaceuticals Ltd. following the satisfaction of all closing conditions required by the merger.
In Nov 2019, Endoceutics announced the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy. INTRAROSA is offered as a vaginal ovule containing 6.5 mg of and prasterone.


Market Trend
  • High Demand for Effective Treatment for Postmenopausal Vaginal Atrophy

Market Drivers
  • Rising Prevalence of Postmenopausal Vaginal Atrophy
  • Growth in the Healthcare Infrastructure in Developing Regions

Opportunities
  • Rising R&D Activities in Postmenopausal Vaginal Atrophy Treatment
  • Growing Healthcare Industry Worldwide
  • Technological Advancements in the Medical Science

Restraints
  • Low Diagnosis Rate

Challenges
  • Stringent Government Rules and Regulations


Key Target Audience
Postmenopausal Vaginal Atrophy Treatment Provider, Potential Investors, Research Firm, Government Bodies, Healthcare Industry and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Drug Form
  • Vaginal gel
  • Creams
  • Tablet
  • Others

By Drug
  • Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring)
  • Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm)
  • Others

By Route of Administration
  • Oral
  • Intravaginal
  • Others

By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Postmenopausal Vaginal Atrophy
      • 3.2.2. Growth in the Healthcare Infrastructure in Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. High Demand for Effective Treatment for Postmenopausal Vaginal Atrophy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Postmenopausal Vaginal Atrophy Treatment, by Drug Form, Drug, Route of Administration, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Postmenopausal Vaginal Atrophy Treatment (Value)
      • 5.2.1. Global Postmenopausal Vaginal Atrophy Treatment by: Drug Form (Value)
        • 5.2.1.1. Vaginal gel
        • 5.2.1.2. Creams
        • 5.2.1.3. Tablet
        • 5.2.1.4. Others
      • 5.2.2. Global Postmenopausal Vaginal Atrophy Treatment by: Drug (Value)
        • 5.2.2.1. Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring)
        • 5.2.2.2. Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm)
        • 5.2.2.3. Others
      • 5.2.3. Global Postmenopausal Vaginal Atrophy Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravaginal
        • 5.2.3.3. Others
      • 5.2.4. Global Postmenopausal Vaginal Atrophy Treatment by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Specialty Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Postmenopausal Vaginal Atrophy Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Postmenopausal Vaginal Atrophy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Actavis Generics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bionovo (Saudi Arabia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Endoceutics, Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Upsher-Smith Laboratories, LLC (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk A/S (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Isreal)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Therapeutics MD, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shionogi & Company, Limited (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Allergan plc (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Ligand Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bayer HealthCare LLC (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Postmenopausal Vaginal Atrophy Treatment Sale, by Drug Form, Drug, Route of Administration, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Postmenopausal Vaginal Atrophy Treatment (Value)
      • 7.2.1. Global Postmenopausal Vaginal Atrophy Treatment by: Drug Form (Value)
        • 7.2.1.1. Vaginal gel
        • 7.2.1.2. Creams
        • 7.2.1.3. Tablet
        • 7.2.1.4. Others
      • 7.2.2. Global Postmenopausal Vaginal Atrophy Treatment by: Drug (Value)
        • 7.2.2.1. Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring)
        • 7.2.2.2. Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm)
        • 7.2.2.3. Others
      • 7.2.3. Global Postmenopausal Vaginal Atrophy Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravaginal
        • 7.2.3.3. Others
      • 7.2.4. Global Postmenopausal Vaginal Atrophy Treatment by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Specialty Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Postmenopausal Vaginal Atrophy Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Postmenopausal Vaginal Atrophy Treatment: by Drug Form(USD Million)
  • Table 2. Postmenopausal Vaginal Atrophy Treatment Vaginal gel , by Region USD Million (2014-2019)
  • Table 3. Postmenopausal Vaginal Atrophy Treatment Creams , by Region USD Million (2014-2019)
  • Table 4. Postmenopausal Vaginal Atrophy Treatment Tablet , by Region USD Million (2014-2019)
  • Table 5. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2014-2019)
  • Table 6. Postmenopausal Vaginal Atrophy Treatment: by Drug(USD Million)
  • Table 7. Postmenopausal Vaginal Atrophy Treatment Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring) , by Region USD Million (2014-2019)
  • Table 8. Postmenopausal Vaginal Atrophy Treatment Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm) , by Region USD Million (2014-2019)
  • Table 9. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2014-2019)
  • Table 10. Postmenopausal Vaginal Atrophy Treatment: by Route of Administration(USD Million)
  • Table 11. Postmenopausal Vaginal Atrophy Treatment Oral , by Region USD Million (2014-2019)
  • Table 12. Postmenopausal Vaginal Atrophy Treatment Intravaginal , by Region USD Million (2014-2019)
  • Table 13. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2014-2019)
  • Table 14. Postmenopausal Vaginal Atrophy Treatment: by End User(USD Million)
  • Table 15. Postmenopausal Vaginal Atrophy Treatment Hospitals , by Region USD Million (2014-2019)
  • Table 16. Postmenopausal Vaginal Atrophy Treatment Specialty Clinics , by Region USD Million (2014-2019)
  • Table 17. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2014-2019)
  • Table 18. South America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2014-2019)
  • Table 19. South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 20. South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 21. South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 22. South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 23. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 24. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 25. Brazil Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 26. Brazil Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 27. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 28. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 29. Argentina Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 30. Argentina Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 31. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 32. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 33. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 34. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 35. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 37. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 38. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 39. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 40. China Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 41. China Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 42. China Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 43. China Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 44. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 45. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 46. Japan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 47. Japan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 48. India Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 49. India Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 50. India Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 51. India Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 52. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 53. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 54. South Korea Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 55. South Korea Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 56. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 57. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 58. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 59. Taiwan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 60. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 61. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 62. Australia Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 63. Australia Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 68. Europe Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2014-2019)
  • Table 69. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 70. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 71. Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 72. Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 73. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 74. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 75. Germany Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 76. Germany Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 77. France Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 78. France Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 79. France Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 80. France Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 81. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 82. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 83. Italy Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 84. Italy Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 85. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 86. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 87. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 88. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 89. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 90. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 91. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 92. Netherlands Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 93. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 94. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 95. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 96. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 97. MEA Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2014-2019)
  • Table 98. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 99. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 100. MEA Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 101. MEA Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 102. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 103. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 104. Middle East Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 105. Middle East Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 106. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 107. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 108. Africa Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 109. Africa Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 110. North America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2014-2019)
  • Table 111. North America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 112. North America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 113. North America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 114. North America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 115. United States Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 116. United States Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 117. United States Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 118. United States Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 119. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 120. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 121. Canada Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 122. Canada Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 123. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2014-2019)
  • Table 124. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2014-2019)
  • Table 125. Mexico Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2014-2019)
  • Table 126. Mexico Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2014-2019)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Postmenopausal Vaginal Atrophy Treatment: by Drug Form(USD Million)
  • Table 140. Postmenopausal Vaginal Atrophy Treatment Vaginal gel , by Region USD Million (2020-2025)
  • Table 141. Postmenopausal Vaginal Atrophy Treatment Creams , by Region USD Million (2020-2025)
  • Table 142. Postmenopausal Vaginal Atrophy Treatment Tablet , by Region USD Million (2020-2025)
  • Table 143. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2020-2025)
  • Table 144. Postmenopausal Vaginal Atrophy Treatment: by Drug(USD Million)
  • Table 145. Postmenopausal Vaginal Atrophy Treatment Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring) , by Region USD Million (2020-2025)
  • Table 146. Postmenopausal Vaginal Atrophy Treatment Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm) , by Region USD Million (2020-2025)
  • Table 147. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2020-2025)
  • Table 148. Postmenopausal Vaginal Atrophy Treatment: by Route of Administration(USD Million)
  • Table 149. Postmenopausal Vaginal Atrophy Treatment Oral , by Region USD Million (2020-2025)
  • Table 150. Postmenopausal Vaginal Atrophy Treatment Intravaginal , by Region USD Million (2020-2025)
  • Table 151. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2020-2025)
  • Table 152. Postmenopausal Vaginal Atrophy Treatment: by End User(USD Million)
  • Table 153. Postmenopausal Vaginal Atrophy Treatment Hospitals , by Region USD Million (2020-2025)
  • Table 154. Postmenopausal Vaginal Atrophy Treatment Specialty Clinics , by Region USD Million (2020-2025)
  • Table 155. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2020-2025)
  • Table 156. South America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2020-2025)
  • Table 157. South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 158. South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 159. South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 160. South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 161. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 162. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 163. Brazil Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 164. Brazil Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 165. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 166. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 167. Argentina Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 168. Argentina Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 169. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 170. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 171. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 172. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 173. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2020-2025)
  • Table 174. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 175. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 176. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 177. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 178. China Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 179. China Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 180. China Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 181. China Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 182. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 183. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 184. Japan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 185. Japan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 186. India Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 187. India Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 188. India Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 189. India Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 190. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 191. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 192. South Korea Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 193. South Korea Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 194. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 195. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 196. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 197. Taiwan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 198. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 199. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 200. Australia Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 201. Australia Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 202. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 203. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 204. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 205. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 206. Europe Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2020-2025)
  • Table 207. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 208. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 209. Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 210. Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 211. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 212. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 213. Germany Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 214. Germany Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 215. France Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 216. France Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 217. France Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 218. France Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 219. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 220. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 221. Italy Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 222. Italy Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 223. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 224. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 225. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 226. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 227. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 228. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 229. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 230. Netherlands Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 231. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 232. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 233. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 234. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 235. MEA Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2020-2025)
  • Table 236. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 237. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 238. MEA Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 239. MEA Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 240. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 241. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 242. Middle East Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 243. Middle East Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 244. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 245. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 246. Africa Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 247. Africa Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 248. North America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2020-2025)
  • Table 249. North America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 250. North America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 251. North America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 252. North America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 253. United States Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 254. United States Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 255. United States Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 256. United States Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 257. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 258. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 259. Canada Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 260. Canada Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 261. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2020-2025)
  • Table 262. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2020-2025)
  • Table 263. Mexico Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2020-2025)
  • Table 264. Mexico Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2020-2025)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Postmenopausal Vaginal Atrophy Treatment: by Drug Form USD Million (2014-2019)
  • Figure 5. Global Postmenopausal Vaginal Atrophy Treatment: by Drug USD Million (2014-2019)
  • Figure 6. Global Postmenopausal Vaginal Atrophy Treatment: by Route of Administration USD Million (2014-2019)
  • Figure 7. Global Postmenopausal Vaginal Atrophy Treatment: by End User USD Million (2014-2019)
  • Figure 8. South America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 9. Asia Pacific Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 10. Europe Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 11. MEA Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 12. North America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 13. Global Postmenopausal Vaginal Atrophy Treatment share by Players 2019 (%)
  • Figure 14. Global Postmenopausal Vaginal Atrophy Treatment share by Players (Top 3) 2019(%)
  • Figure 15. Global Postmenopausal Vaginal Atrophy Treatment share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Actavis Generics (United States) Revenue, Net Income and Gross profit
  • Figure 18. Actavis Generics (United States) Revenue: by Geography 2019
  • Figure 19. Bionovo (Saudi Arabia) Revenue, Net Income and Gross profit
  • Figure 20. Bionovo (Saudi Arabia) Revenue: by Geography 2019
  • Figure 21. Endoceutics, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Endoceutics, Inc. (Canada) Revenue: by Geography 2019
  • Figure 23. Upsher-Smith Laboratories, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 24. Upsher-Smith Laboratories, LLC (United States) Revenue: by Geography 2019
  • Figure 25. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 26. Novo Nordisk A/S (Denmark) Revenue: by Geography 2019
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue: by Geography 2019
  • Figure 31. Therapeutics MD, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Therapeutics MD, Inc. (United States) Revenue: by Geography 2019
  • Figure 33. Shionogi & Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Shionogi & Company, Limited (Japan) Revenue: by Geography 2019
  • Figure 35. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 36. Allergan plc (Ireland) Revenue: by Geography 2019
  • Figure 37. Ligand Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 38. Ligand Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 39. Bayer HealthCare LLC (United States) Revenue, Net Income and Gross profit
  • Figure 40. Bayer HealthCare LLC (United States) Revenue: by Geography 2019
  • Figure 41. Global Postmenopausal Vaginal Atrophy Treatment: by Drug Form USD Million (2020-2025)
  • Figure 42. Global Postmenopausal Vaginal Atrophy Treatment: by Drug USD Million (2020-2025)
  • Figure 43. Global Postmenopausal Vaginal Atrophy Treatment: by Route of Administration USD Million (2020-2025)
  • Figure 44. Global Postmenopausal Vaginal Atrophy Treatment: by End User USD Million (2020-2025)
  • Figure 45. South America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 46. Asia Pacific Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 47. Europe Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 48. MEA Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 49. North America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Actavis Generics (United States)
  • Bionovo (Saudi Arabia)
  • Endoceutics, Inc. (Canada)
  • Upsher-Smith Laboratories, LLC (United States)
  • Novo Nordisk A/S (Denmark)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Isreal)
  • Therapeutics MD, Inc. (United States)
  • Shionogi & Company, Limited (Japan)
  • Allergan plc (Ireland)
  • Ligand Pharmaceuticals (United States)
  • Bayer HealthCare LLC (United States)
Additional players considered in the study are as follows:
Pantarhei Bioscience (Netherland) , VYNE Therapeutics Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation